132 related articles for article (PubMed ID: 34794654)
1. 3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
van Hemert ND; Voskuil M; Rozemeijer R; Stein M; Frambach P; Pereira B; Rittersma SZ; Kraaijeveld AO; Leenders GEH; Timmers L; van der Harst P; Agostoni P; Stella PR;
JACC Cardiovasc Interv; 2021 Nov; 14(22):2477-2486. PubMed ID: 34794654
[TBL] [Abstract][Full Text] [Related]
2. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of contemporary drug-eluting stent implantation in diabetic patients: Subanalysis of a randomized controlled trial.
van Hemert ND; Voskuil M; Rozemeijer R; Kraaijeveld AO; Rittersma SZ; Leenders GEH; Stein M; Frambach P; van der Harst P; Agostoni P; Stella PR;
Catheter Cardiovasc Interv; 2023 Feb; 101(3):505-510. PubMed ID: 36651339
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes after permanent polymer or polymer-free stent implantation in patients with diabetes mellitus: The ReCre8 diabetes substudy.
van Hemert ND; Rozemeijer R; Voskuil M; Stein M; Frambach P; Rittersma SZ; Kraaijeveld AO; Leenders GEH; van der Harst P; Agostoni P; Stella PR;
Catheter Cardiovasc Interv; 2022 Feb; 99(2):366-372. PubMed ID: 33811730
[TBL] [Abstract][Full Text] [Related]
5. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R; Stein M; Frambach P; Voskuil M; Kraaijeveld AO; Rodríguez-Olivares R; Timmers L; Pereira B; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
Catheter Cardiovasc Interv; 2018 Feb; 91(3):410-416. PubMed ID: 28544782
[TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
[TBL] [Abstract][Full Text] [Related]
8. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
9. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
10. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
[TBL] [Abstract][Full Text] [Related]
11. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
12. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
15. Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus.
Godino C; Pivato CA; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Milazzo D; Parisi R; Nicolino A; Moshiri S; Aprigliano G; Palloshi A; Zavalloni Parenti D; Rutigliano D; Locuratolo N; Melillo F; Scotti A; Arrigoni L; Montorfano M; Fattori R; Presbitero P; Sardella G; Bedogni F; Margonato A; Briguori C; Colombo A;
Int J Cardiol; 2017 Oct; 245():69-76. PubMed ID: 28874301
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.
Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S;
Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
18. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial.
Kim SH; Kang SH; Lee JM; Chung WY; Park JJ; Yoon CH; Suh JW; Cho YS; Doh JH; Cho JM; Bae JW; Youn TJ; Chae IH
Catheter Cardiovasc Interv; 2020 Dec; 96(7):1399-1406. PubMed ID: 31859438
[TBL] [Abstract][Full Text] [Related]
19. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B; Saito Y; Baumbach A; Kelbæk H; van Royen N; Zheng M; Morel MA; Knaapen P; Slagboom T; Johnson TW; Vlachojannis G; Arkenbout KE; Holmvang L; Janssens L; Ochala A; Brugaletta S; Naber CK; Anderson R; Rittger H; Berti S; Barbato E; Toth GG; Maillard L; Valina C; Buszman P; Thiele H; Schächinger V; Lansky A; Wijns W;
JACC Cardiovasc Interv; 2019 Sep; 12(17):1679-1687. PubMed ID: 31129092
[TBL] [Abstract][Full Text] [Related]
20. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
